Latest from Telomir

Thu Apr 30, 2026 08:00 am

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Select Year:
Mon Jun 17, 2024 04:10 pm

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Thu May 30, 2024 08:30 am

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Tue Apr 16, 2024 08:30 am

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Tue Apr 2, 2024 08:30 am

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Fri Mar 29, 2024 04:44 pm

UPDATE - Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Tue Mar 26, 2024 08:30 am

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Fri Mar 22, 2024 08:30 am

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Thu Mar 14, 2024 08:30 am

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Thu Mar 7, 2024 08:30 am

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Tue Mar 5, 2024 08:30 am

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

1 … 4 5 6 7